



Final Appraisal Recommendation

Advice number: 1222 – July 2022

Elbasvir/grazoprevir (Zepatier®) 50 mg/100 mg film coated tablets

Submission by Merck Sharp & Dohme (UK) Limited

Recommendation of the All Wales Medicines Strategy Group

Elbasvir/grazoprevir (Zepatier®) is recommended as an option for use within NHS Wales for the treatment of genotype 1 or 4 chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg.

Additional note(s):

- See NICE guidance for elbasvir/grazoprevir (Zepatier®) for the treatment of genotype 1 or 4 chronic hepatitis C in adults (TA413, originally published October 2016).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4980), which includes the All Wales Toxicology and Therapeutics Centre (AWTTC) assessment form, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1222:

Elbasvir/grazoprevir (Zepatier®) 50 mg/100 mg film coated tablets July 2022